Description
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on developing cancer therapies.
The Company's six investigational products are in the clinical development, with its molecule, an anti-TIGIT antibody, which is in two phase III registrational studies. The Company's differentiated combination therapies are developing to treat multiple large tumor types, including lung, colorectal, prostate and pancreatic cancers.
Its clinical development pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Zimberelimab and AB521. Domvanalimab is its Fc-silent anti-TIGIT monoclonal antibody. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors. Quemliclustat is an extremely potent and selective small-molecule CD73 inhibitor. Zimberelimab is its anti-PD-1 antibody.